Rebecca Goydel serves as the Scientific Director of Business Development at Abzena, where she expertly bridges the gap between cutting-edge scientific research and strategic business initiatives. With a PhD in antibody engineering, Rebecca has a profound understanding of the complexities involved in bioconjugate and biologics...
Rebecca Goydel serves as the Scientific Director of Business Development at Abzena, where she expertly bridges the gap between cutting-edge scientific research and strategic business initiatives. With a PhD in antibody engineering, Rebecca has a profound understanding of the complexities involved in bioconjugate and biologics development. Her role is pivotal in driving the company's mission to advance novel treatments from discovery through to commercial launch, ensuring that Abzena remains at the forefront of the biopharmaceutical industry.
In her capacity as Scientific Director, Rebecca leads key projects that involve the integration of scientific insights into business strategies, thereby enhancing client relationships and fostering collaboration across departments. Her proven track record as an Antibody Discovery Team Lead demonstrates her ability to manage successful campaigns while promoting cross-functional teamwork. This experience is complemented by her expertise in intellectual property management, contract negotiation, and corporate communication, which ensures that projects align with both scientific and business objectives.
Rebecca's strong interpersonal skills enable her to communicate complex scientific concepts effectively to diverse stakeholders, facilitating informed decision-making and strategic planning. Her proficiency in project management and critical thinking allows her to navigate the challenges of the rapidly evolving biotech landscape, ensuring that Abzena can tailor its strategies to meet the unique needs of each client. As a leader in scientific communications, she is committed to driving innovation and delivering impactful solutions that empower biotech and biopharma companies to realize their therapeutic visions.
